Relevant bibliographies by topics / Nanostructured lipid carriers

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Nanostructured lipid carriers'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nanostructured lipid carriers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nanostructured lipid carriers"

1

Viegas, Cláudia, Ana B. Patrício, João M. Prata, Akhtar Nadhman, Pavan Kumar Chintamaneni, and Pedro Fonte. "Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review." Pharmaceutics 15, no. 6 (2023): 1593. http://dx.doi.org/10.3390/pharmaceutics15061593.

Full text
Abstract:
Solid–lipid nanoparticles and nanostructured lipid carriers are delivery systems for the delivery of drugs and other bioactives used in diagnosis, therapy, and treatment procedures. These nanocarriers may enhance the solubility and permeability of drugs, increase their bioavailability, and extend the residence time in the body, combining low toxicity with a targeted delivery. Nanostructured lipid carriers are the second generation of lipid nanoparticles differing from solid lipid nanoparticles in their composition matrix. The use of a liquid lipid together with a solid lipid in nanostructured lipid carrier allows it to load a higher amount of drug, enhance drug release properties, and increase its stability. Therefore, a direct comparison between solid lipid nanoparticles and nanostructured lipid carriers is needed. This review aims to describe solid lipid nanoparticles and nanostructured lipid carriers as drug delivery systems, comparing both, while systematically elucidating their production methodologies, physicochemical characterization, and in vitro and in vivo performance. In addition, the toxicity concerns of these systems are focused on.
APA, Harvard, Vancouver, ISO, and other styles
2

Ghazwani, Mohammed, Umme Hani, Mohammed H. Alqarni, and Aftab Alam. "Beta Caryophyllene-Loaded Nanostructured Lipid Carriers for Topical Management of Skin Disorders: Statistical Optimization, In Vitro and Dermatokinetic Evaluation." Gels 9, no. 7 (2023): 550. http://dx.doi.org/10.3390/gels9070550.

Full text
Abstract:
This work aimed to overcome the disadvantages of the oral administration of beta-caryophyllene and boost efficiency by developing a nanostructured lipid carrier for topical administration of the drug in skin disorders. The heat emulsification method was utilized to produce beta-caryophyllene-loaded nanostructured lipid carriers. The newly created formulation was examined for its particle size, entrapment efficiency, and zeta potential after being improved using the Box–Behnken Design. The chosen formulation underwent tests to determine its ex vivo skin retention, dermatokinetic, in vitro release, antioxidant, and confocal laser scanning microscopy study. The findings of the characterization of the nanostructured lipid carriers demonstrated that the particles had a spherical form and a size of 210.86 nm (0.263 polydispersity index). The entrapment efficiency was determined to be 86.74%, and the zeta potential was measured to be −26.97 mV. The in vitro release investigation showed that nanostructure lipid carriers were capable of releasing regulated amounts of beta-caryophyllene for up to 24 hrs. In comparison to the traditional gel formulation, the ex vivo investigation demonstrated a 1.94-fold increase in the skin’s capacity to retain the substance. According to the findings of the study, nanostructure lipid carriers loaded with beta-caryophyllene have the potential to be investigated for use as a topical administration method in skin disorders with enhanced skin retention and effectiveness.
APA, Harvard, Vancouver, ISO, and other styles
3

Olerile, Livesey D. "Further Development of Near-Infrared Mediated Quantum Dots and Paclitaxel Co-loaded Nanostructured Lipid Carrier System for Cancer Theragnostic." Technology in Cancer Research & Treatment 19 (January 1, 2020): 153303382091430. http://dx.doi.org/10.1177/1533033820914308.

Full text
Abstract:
Of colloidal systems, ceteris paribus, nanostructured lipid carriers are second to none in offering a single-unit platform for multifunctional benefits. Quantum dots are known to possess unique properties that make them ideal for imaging purpose and that they may be used for cancer detection. For several decades, paclitaxel has been the most effective drug against a wide range of solid tumours. Theragnostic nanomedicine provides a platform to monitor, evaluate, and individualize treatment in real time. Evaluation of cancer treatment outcome at an early stage therapy is key to increase survival prospects of a patient. Previously, a novel co-loaded nanostructured lipid carriers’ theragnostic system for parenteral administration was developed. The aim of this study was to further investigate the co-loaded nanostructured lipid carriers in order to provide interpretation necessary for preclinical elucidation of the formulation, in part. The co-loaded nanostructured lipid carriers were prepared by oil/water emulsification-solvent evaporation technique. In this study, stability and co-loaded nanostructured lipid carriers’ internalization by MCF 7 and HepG2 cells were investigated. The co-loaded nanostructured lipid carriers was stable at 4°C for 1 month. The formulation was successfully internalized by MCF-7 and HepG2 cells. Nevertheless, the co-loaded nanostructured lipid carrier was more apt for MCF-7 cells. This finding affirms the formulation to be the most appropriate for breast cancer treatment. In addition, if taken correctly by a patient for a month, the formulation would give true reflection of the contents’ amounts, the factor paramount to appropriate changes in treatment protocol. It can therefore safely be concluded that the co-loaded nanostructured lipid carrier formulation may be potentially an effective theragnostic translational system.
APA, Harvard, Vancouver, ISO, and other styles
4

Aryani, Ni Luh Dewi, Siswandono Siswandono, Wdji Soeratri, Dian Yulyandani Putri, and Pingky Dwi Puspitasarini. "Development, characterization in vitro and in silico of coenzyme Q10 loaded myristic acid with different liquid lipids nanostructured lipid carriers." Journal of Pharmacy & Pharmacognosy Research 9, no. 5 (2021): 573–83. http://dx.doi.org/10.56499/jppres21.1038_9.5.573.

Full text
Abstract:
Context: Nanostructured lipid carriers can enhance skin penetration of active substances. Coenzyme Q10 is a lipophilic antioxidant, that has poor skin penetration. This limitation is overcome by nanostructured lipid carriers. Aims: To developed coenzyme Q10 nanostructured lipid carriers using myristic acid with various liquid lipids as lipid matrix by in vitro studies and in silico approach for explaining the interaction of coenzyme Q10-lipid at the molecular level. Methods: The coenzyme Q10 nanostructured lipid carriers were prepared using myristic acid as solid lipid with oleic acid, isopropyl myristate, and isopropyl palmitate as liquid lipids using the high shear homogenization method. Then, they were evaluated in physicochemical characteristics by dynamic light scattering, differential scanning calorimetry, Fourier transforms infrared, scanning electron microscopy, spectrophotometry ultraviolet-visible, and pH meter. Furthermore, the in silico studies were conducted using AutoDock 4.2. Results: The coenzyme Q10 nanostructured lipid carriers using myristic acid-oleic acid, myristic acid-isopropyl myristate, and myristic acid-isopropyl palmitate as lipid matrix had the mean particle size, polydispersity index, entrapment efficiency, drug loading, and pH value were less than 300 nm, less than 0.3, more than 80%, about 10%, and about 5.0, respectively. Moreover, molecular docking of coenzyme Q10 and lipid showed hydrogen and hydrophobic bonds. These results supported differential scanning calorimetry and Fourier transforms infrared results. Conclusions: The coenzyme Q10 nanostructured lipid carriers were successfully prepared using myristic acid-oleic acid, myristic acid-isopropyl myristate, and myristic acid-isopropyl palmitate as lipid matrix as well as in silico study could be used for explaining of coenzyme Q10-lipid interaction.
APA, Harvard, Vancouver, ISO, and other styles
5

Rochman, M. Fatchur, Aditya Darmawan, and Pramudya Wardhana. "Nanostructured Lipid Carriers System Solid Lipid Poloxamer and Stearic Acid with Liquid Lipid Soybean Oil." Jurnal Ilmiah Medicamento 8, no. 1 (2022): 1–7. http://dx.doi.org/10.36733/medicamento.v8i1.3161.

Full text
Abstract:
Nanostructured Lipid Carriers (NLC) are lipid-based carrier system that use a matrix combination in the form of solid and liquid which are stabilized with the addition of surfactant. This NLC was developed to facilitate the dispersion of hydrophobic bioactive compound in a hydrophilic system. This research aims to get the right formulation and can develop stable characterization, using solid lipids Poloxamer and Stearic Acid with liquid lipids Soybeans Oil using surfactant Tween 80 and co-surfactant Propyleneglycol.. The to make the formulation of NLC with a ratio of poloxamer and stearic acid as solid lipid: soybeans oil asliquid lipid is 3:3, 4:2, 5:1 ,surfactant tween 80 and co surfactant propyleneglycol. Test the NLC characterization including PH value, viscosity, particle size, and polydispersity index. Data analysis used to evaluate the characteristics of the obtained NLC using descriptive. The result of the research showed that NLC had good characteistics at a solid lipid poloxamer and stearic acid with Soybean oil liquid lipid ,pH in the range 4-6; good viscosity; good particles have a range of 1000nm; and polydispersity index which shows the results of monodispersion. Nanostructured Llipid Carriers with solid lipid poloxamer and stearic acid and liquid lipid soybean oil obtained good characteristics.
APA, Harvard, Vancouver, ISO, and other styles
6

Sathyanaryana, Thulasi, and Preethi Sudheer. "NANOSTRUCTURED LIPID CARRIERS: A NOVEL STRATEGY FOR TRANSDERMAL DRUG DELIVERY SYSTEMS." Indian Drugs 59, no. 10 (2022): 7–19. http://dx.doi.org/10.53879/id.59.10.12532.

Full text
Abstract:
Drug administration via the skin is one of the most conventionally used methods where the flux through the skin is the rate-limiting step. Safe carriers are used to provide the anticipated therapeutic effects, which play a vital role in drug delivery. A nanostructured lipid carrier (NLC) is a binary mixture of solid and liquid lipids and surfactants. The lipid nature and nano size of these carriers contribute to the skin penetration of therapeutic agents. These carriers have a wide variety of advantages, such as good biocompatibility, low cytotoxicity, high drug quality and increased stability. This paper deliberates the suitability of NLCs in transdermal drug delivery, their properties, the methods of preparation and their applications.
APA, Harvard, Vancouver, ISO, and other styles
7

Esposito, Elisabetta, Maddalena Sguizzato, Markus Drechsler, et al. "Lipid nanostructures for antioxidant delivery: a comparative preformulation study." Beilstein Journal of Nanotechnology 10 (August 29, 2019): 1789–801. http://dx.doi.org/10.3762/bjnano.10.174.

Full text
Abstract:
This investigation is a study of new lipid nanoparticles for cutaneous antioxidant delivery. Several molecules, such as α-tocopherol and retinoic acid, have been shown to improve skin condition and even counteract the effects of exogenous stress factors such as smoking on skin aging. This work describes the design and development of lipid nanoparticles containing antioxidant agents (α-tocopherol or retinoic acid) to protect human skin against pollutants. Namely, solid lipid nanoparticles and nanostructured lipid carriers were prepared using different lipids (tristearin, compritol, precirol or suppocire) in the presence or absence of caprylic/capric triglycerides. The formulations were characterized by particle size analysis, cryogenic transmission electron microscopy, small-angle X-ray diffraction, encapsulation efficiency, preliminary stability, in vitro cytotoxicity and protection against cigarette smoke. Nanostructured lipid carriers were found to reduce agglomerate formation and provided better dimensional stability, as compared to solid lipid nanoparticles, suggesting their suitability for antioxidant loading. Based on the preformulation study, tristearin-based nanostructured lipid carriers loaded with α-tocopherol were selected for ex vivo studies since they displayed superior physico-chemical properties as compared to the other nanostructured lipid carriers compositions. Human skin explants were treated with α-tocopherol-loaded nanostructured lipid carriers and then exposed to cigarette smoke, and the protein levels of the stress-induced enzyme heme oxygenase were analyzed in skin homogenates. Interestingly, it was found that pretreatment with the nanoformulation resulted in significantly reduced heme oxygenase upregulation as compared to control samples, suggesting a protective effect provided by the nanoparticles.
APA, Harvard, Vancouver, ISO, and other styles
8

Makoni, Pedzisai A., Kasongo Wa Kasongo, and Roderick B. Walker. "Short Term Stability Testing of Efavirenz-Loaded Solid Lipid Nanoparticle (SLN) and Nanostructured Lipid Carrier (NLC) Dispersions." Pharmaceutics 11, no. 8 (2019): 397. http://dx.doi.org/10.3390/pharmaceutics11080397.

Full text
Abstract:
The short term stability of efavirenz-loaded solid lipid nanoparticle and nanostructured lipid carrier dispersions was investigated. Hot High Pressure Homogenization with the capability for scale up production was successfully used to manufacture the nanocarriers without the use of toxic organic solvents for the first time. Glyceryl monostearate and Transcutol® HP were used as the solid and liquid lipids. Tween® 80 was used to stabilize the lipid nanocarriers. A Box-Behnken Design was used to identify the optimum operating and production conditions viz., 1100 bar for 3 cycles for the solid lipid nanoparticles and 1500 bar for 5 cycles for nanostructured lipid carriers. The optimized nanocarriers were predicted to exhibit 10% efavirenz loading with 3% and 4% Tween® 80 for solid lipid nanoparticles and nanostructured lipid carriers, respectively. Characterization of the optimized solid lipid nanoparticle and nanostructured lipid carrier formulations in relation to shape, surface morphology, polymorphism, crystallinity and compatibility revealed stable formulations with particle sizes in the nanometer range had been produced. The nanocarriers had excellent efavirenz loading with the encapsulation efficiency >90%. The optimized nanocarriers exhibited biphasic in vitro release patterns with an initial burst release during the initial 0–3 h followed by sustained release over a 24 h period The colloidal systems showed excellent stability in terms of Zeta potential, particle size, polydispersity index and encapsulation efficiency when stored for 8 weeks at 25 °C/60% RH in comparison to when stored at 40 °C/75% RH. The formulations manufactured using the optimized conditions and composition proved to be physically stable as aqueous dispersions.
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Yulin, Ping Ma, and Shuangying Gui. "Cubic and Hexagonal Liquid Crystals as Drug Delivery Systems." BioMed Research International 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/815981.

Full text
Abstract:
Lipids have been widely used as main constituents in various drug delivery systems, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-based lyotropic liquid crystals. Among them, lipid-based lyotropic liquid crystals have highly ordered, thermodynamically stable internal nanostructure, thereby offering the potential as a sustained drug release matrix. The intricate nanostructures of the cubic phase and hexagonal phase have been shown to provide diffusion controlled release of active pharmaceutical ingredients with a wide range of molecular weights and polarities. In addition, the biodegradable and biocompatible nature of lipids demonstrates the minimum toxicity and thus they are used for various routes of administration. Therefore, the research on lipid-based lyotropic liquid crystalline phases has attracted a lot of attention in recent years. This review will provide an overview of the lipids used to prepare cubic phase and hexagonal phase at physiological temperature, as well as the influencing factors on the phase transition of liquid crystals. In particular, the most current research progresses on cubic and hexagonal phases as drug delivery systems will be discussed.
APA, Harvard, Vancouver, ISO, and other styles
10

Kavita Rani, Amit Kumar J. Raval, Dinesh Kaushik, and Rajesh Khathuriya. "Formulation of Nanostructured lipid particles." Asian Pacific Journal of Nursing and Health Sciences 3, no. 2 (2020): 20–24. http://dx.doi.org/10.46811/apjnh/3.2.4.

Full text
Abstract:
Lipid nanocarriers are developed as an alternative to polymeric nanoparticles, liposomes and emulsions. NLCs are the second generation lipid carriers developed to overcome problems associated with Solid Lipid Nanoparticles and are utilized in various therapeutic approaches. NLCs were used for the delivery of lipophilic drugs .Biocompatible nature of lipids is responsible for its development as a good drug delivery. It was found to be having excellent characteristics over other lipid formulations.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Nanostructured lipid carriers"

1

Karmakar, Gourab. "Physicochemical investigation on Nanostructural Lipid Carriers." Thesis, University of North Bengal, 2018. http://ir.nbu.ac.in/handle/123456789/2855.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

RAVANI, Laura. "FOCUS ON NANOSTRUCTURED LIPID CARRIERS AND MONOOLEIN AQUEOUS DISPERSIONS." Doctoral thesis, Università degli studi di Ferrara, 2012. http://hdl.handle.net/11392/2389252.

Full text
Abstract:
Nowadays, everyone feels the impact of nanotechnology in his life. There is a trend that urges people to revisit many research areas with a nano-view, in order to understand how the same thing can work at nano- level. This phenomenon is revolutionizing pharmaceutical sciences and many drugs are being reformulated for possibilities of delivering as a nanosystem. In recent years, a particular attention has been focused on new generations of lipid nanoparticles such as nanostructured lipid carriers (NLC), a second generation of solid lipid nanoparticles (SLN), and monoolein aqueous dispersions (MAD), derived from the mesophases originated from the system monoolein/water/poloxamer. In this thesis different NLC, SLN or MAD formulations were developed as drug delivery systems specifically for antiparkinson or antimycotic drugs, in order to prolong their action and reduce the side effects. Bromocriptine (BC), new synthetized L-DOPA derivatives (Der-A, Der-B, Der-C and Der-D) or Clotrimazole (CLO) have been alternatively chosen as model drugs. Physical and chemical characterizations have been performed on the obtained formulations. In vitro and in vivo studies permitted to obtain release kinetics and evaluate the effectiveness of nanoparticulate systems. BC containing NLC and MAD showed high entrapment efficiency and X-ray diffraction analyses demonstrated that the presence of BC did not affect the scattering profile. In this case, different in vitro experimental approaches were evaluated, showing that the in vitro release of poorly water soluble drugs (as BC) is more affected by the composition of the receiving phase (i.e. in term of presence of water miscible polar organic solvents) rather than by the experi modality adopted for the in vitro determinations. In vivo studies demonstrated that only BC-NLC were able to markedly attenuate motor deficit in 6-OHDA hemilesioned rats, suggesting that NLC represent a more effective carrier to prolong the half-life of BC in vivo. All L-DOPA derivatives were successfully incorporated in NLC. The produced formulations resulted homogeneous in terms of size and remain stable until two months from the preparation. Morphological characterization highlighted that no substantial difference characterized empty and derivatives containing NLC. In vitro kinetics release highlighted that NLC were able to release the contained derivatives in a controlled manner and permit to select Der-A for in vivo tests. In vivo tests demonstrated that the Der-A possess antiparkinson activity. The inclusion of Der-A in SLN, performed using three different concentrations of prodrug, showed different entrapment efficiencies depending on the quantity of active employed. Calorimetric test evidenced an effective interaction between lipid phase and the prodrug. In vitro studies demonstrated a controlled release of Der-A from SLN, also thanks to the extension of the half-life of the prodrug. CLO was incorporated both in MAD and in NLC with high recovery. Shelf life stability evidenced that the solid matrix of NLC enabled to control drug degradation better than MAD. In vitro experiments on candida cells demonstrated that CLO-MAD and CLO-NLC exhibit a higher activity than the free drug. The gelification of CLO containing nanoparticles permitted to obtain formulations able to remain on the mucosa surface. Micro calorimetric assays confirmed that poloxamer formulated gels are able to change their structure, with a rapid passage from liquid to solid (crystalline) form at a temperature lower than vaginal temperature, allowing a selective action in the site of application. Finally it is noteworthy that the production of CLO-NLC poloxamer gel is simple and suitable for industry scaling up.
APA, Harvard, Vancouver, ISO, and other styles
3

Pardeike, Jana [Verfasser]. "Nanosuspensions and nanostructured lipid carriers for dermal application / Jana Pardeike." Berlin : Freie Universität Berlin, 2009. http://d-nb.info/1023465523/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Prazeres, Inês. "Development of astaxanthin lipid formulations for nutraceutical application: targeting the gastrointestinal epithelium." Master's thesis, Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier, 2019. http://hdl.handle.net/10362/130075.

Full text
Abstract:
Dissertation presented to obtain the Master degree in Biochemistry for Health<br>"Astaxanthin is renowned for its powerful antioxidant activity and remarkable therapeutic effects in the prevention and treatment of several diseases. Moreover, astaxanthin could constitute a potential nutraceutical to be used in the treatment and maintenance of Inflammatory Bowel Diseases. However, its therapeutic use is seriously limited by its instability and low bioavailability. Hence, in this work, astaxanthin and a shrimp shells extract rich in astaxanthin were entrapped into nanostructured lipid carriers (NLCs) and structured lipid carriers (SLCs). Furthermore, their permeability was assessed in a Caco-2 monoculture and in a Caco-2:HT29-MTX:Raji-B triple co-culture. Additionally, their capacity to inhibit reactive species of oxygen (ROS) formation was assessed in Caco-2 monolayers.(...)"<br>N/A
APA, Harvard, Vancouver, ISO, and other styles
5

Hommoss, Aiman [Verfasser]. "Nanostructured Lipid Carriers (NLC) in dermal and personal care formulations / Aiman Hommoss." Berlin : Freie Universität Berlin, 2009. http://d-nb.info/1023465574/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Santos, Fernanda Kolenyak dos. "Desenvolvimento e caracterização de carreadores lipídicos nanoestruturados contendo praziquantel /." Araraquara : [s.n.], 2011. http://hdl.handle.net/11449/96245.

Full text
Abstract:
Orientador: Maria Palmira Daflon Gremião<br>Banca: Beatriz Stringhetti Ferreira Cury<br>Banca: Silmara Marques Alegretti<br>Resumo: A esquistossomose é uma doença que atinge cerca de 200 milhões de pessoas no mundo todo. A alta incidência desta doença está ligada à falta de condições sanitárias, ao diagnóstico tardio e, principalmente, à falta de tratamento medicamentoso eficiente. O praziquantel é o fármaco de primeira escolha para o tratamento da esquistossomose. No entanto, falhas no tratamento com este fármaco e relatos de isolamento de S. mansoni tolerantes podem comprometer a eficiência do PZQ. Assim, o PZQ representa um fármaco em que pesquisas para melhorar as suas propriedades biofarmacêuticas são necessárias, pois apresenta baixa solubilidade em meio aquoso e biodisponibilidade baixa ou errática. O presente trabalho vê como finalidade desenvolver carreadores lipídicos nanoestruturados (NLC) contendo praziquantel empregando como sistema lipídico o monoestearato de glicerila (GMS) e o ácido oléico (AO) e como sistema tensoativo a associações de monoestearato de polioxietileno sorbitano 60 (TWEEN60), fosfatidilcolina, Poloxamer (Pluronic F-127 PLU). Os NLCs foram preparados através de dois diferentes métodos, de sonicação e alta velocidade de cisalhamento a quente. Os sistemas foram caracterizados através da avaliação dos parâmetros de distribuição de tamanho, potencial zeta, índice de polidispersidade e eficiência de encapsulação. O transporte intestinal do fármaco foi avaliado através do modelo do saco intestinal invertido. Ambos os métodos de obtenção empregados mostraram-se eficazes para o preparo dos NLCs em escala nanometrica, com índice de polidispersidade homogeneo e um... (Resumo completo, clicar acesso eletrônico abaixo)<br>Abstract: The Schistosomiasis is a debilitating disease with high misfit in the quality of people life reached about 200 million people worldwide. The high incidence of this disease is linked to poor sanitary conditions, late diagnosis, and especially the lack of effective drug treatment. Praziquantel is the drug of first choice for treatment of schistosomiasis. However, treatment failures with this drug and reports of isolation of S. mansoni tolerance may compromise the efficiency of PZQ. Thus, the PZQ represents an example in which surveys to improve the biopharmaceutical properties are needed, since it has low solubility in aqueous and low or erratic bioavailability. This work aims to develop nanostructured lipid carriers (NLC) containing praziquantel employing as lipid system the glycerin monostearate (GMS) and oleic acid (OA) as a surfactant system and some combination of polyoxyethylene sorbitan monostearate 60 (TWEEN60), phosphatidylcholine and Poloxamer (Pluronic F-127 PLU) as a surfactant system. NLCs were prepared by two different methodologies, the sonication and high shear rates to warm. The systems were characterized by determination of size distribution, zeta potential, polydispersity index and encapsulation efficiency. The intestinal transport of the drug was evaluate by using the model of inverted intestinal sac. Both methods were effective for the preparation of NLCs with an average diameter in the nanometer range, the polydispersity index indicating homogeneity of particle size and a zeta... (Complete abstract click electronic access below)<br>Mestre
APA, Harvard, Vancouver, ISO, and other styles
7

Santos, Fernanda Kolenyak dos [UNESP]. "Desenvolvimento e caracterização de carreadores lipídicos nanoestruturados contendo praziquantel." Universidade Estadual Paulista (UNESP), 2011. http://hdl.handle.net/11449/96245.

Full text
Abstract:
Made available in DSpace on 2014-06-11T19:28:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-01-20Bitstream added on 2014-06-13T20:57:40Z : No. of bitstreams: 1 santos_fk_me_arafcf.pdf: 504042 bytes, checksum: ff6921c63666c7dee3c57494e9ca1b8f (MD5)<br>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)<br>Universidade Estadual Paulista (UNESP)<br>A esquistossomose é uma doença que atinge cerca de 200 milhões de pessoas no mundo todo. A alta incidência desta doença está ligada à falta de condições sanitárias, ao diagnóstico tardio e, principalmente, à falta de tratamento medicamentoso eficiente. O praziquantel é o fármaco de primeira escolha para o tratamento da esquistossomose. No entanto, falhas no tratamento com este fármaco e relatos de isolamento de S. mansoni tolerantes podem comprometer a eficiência do PZQ. Assim, o PZQ representa um fármaco em que pesquisas para melhorar as suas propriedades biofarmacêuticas são necessárias, pois apresenta baixa solubilidade em meio aquoso e biodisponibilidade baixa ou errática. O presente trabalho vê como finalidade desenvolver carreadores lipídicos nanoestruturados (NLC) contendo praziquantel empregando como sistema lipídico o monoestearato de glicerila (GMS) e o ácido oléico (AO) e como sistema tensoativo a associações de monoestearato de polioxietileno sorbitano 60 (TWEEN60), fosfatidilcolina, Poloxamer (Pluronic F-127 PLU). Os NLCs foram preparados através de dois diferentes métodos, de sonicação e alta velocidade de cisalhamento a quente. Os sistemas foram caracterizados através da avaliação dos parâmetros de distribuição de tamanho, potencial zeta, índice de polidispersidade e eficiência de encapsulação. O transporte intestinal do fármaco foi avaliado através do modelo do saco intestinal invertido. Ambos os métodos de obtenção empregados mostraram-se eficazes para o preparo dos NLCs em escala nanometrica, com índice de polidispersidade homogeneo e um...<br>The Schistosomiasis is a debilitating disease with high misfit in the quality of people life reached about 200 million people worldwide. The high incidence of this disease is linked to poor sanitary conditions, late diagnosis, and especially the lack of effective drug treatment. Praziquantel is the drug of first choice for treatment of schistosomiasis. However, treatment failures with this drug and reports of isolation of S. mansoni tolerance may compromise the efficiency of PZQ. Thus, the PZQ represents an example in which surveys to improve the biopharmaceutical properties are needed, since it has low solubility in aqueous and low or erratic bioavailability. This work aims to develop nanostructured lipid carriers (NLC) containing praziquantel employing as lipid system the glycerin monostearate (GMS) and oleic acid (OA) as a surfactant system and some combination of polyoxyethylene sorbitan monostearate 60 (TWEEN60), phosphatidylcholine and Poloxamer (Pluronic F-127 PLU) as a surfactant system. NLCs were prepared by two different methodologies, the sonication and high shear rates to warm. The systems were characterized by determination of size distribution, zeta potential, polydispersity index and encapsulation efficiency. The intestinal transport of the drug was evaluate by using the model of inverted intestinal sac. Both methods were effective for the preparation of NLCs with an average diameter in the nanometer range, the polydispersity index indicating homogeneity of particle size and a zeta... (Complete abstract click electronic access below)
APA, Harvard, Vancouver, ISO, and other styles
8

Antunes, Débora Ribeiro. "Preparo e caracterização de nanocarreadores lipídicos híbridos visando a liberação controlada do herbicida atrazina /." Ilha Solteira, 2020. http://hdl.handle.net/11449/192544.

Full text
Abstract:
Orientador: Renato Grillo<br>Resumo: Inúmeros sistemas nanoestruturados vêm sendo desenvolvidos para o transporte e liberação modificada de defensivos agrícolas nos últimos anos. Tais sistemas vêm se mostrando uma potencial ferramenta para reduzir a toxicidade destes ingredientes ativos no ambiente, bem como vêm melhorando a eficiência de pesticidas no campo. Entretanto pouco se conhece sobre o destino, toxicidade e mecanismos de ação destes nanocarreadores no ambiente. Neste sentido, o objetivo do presente trabalho foi desenvolver potenciais sistemas de liberação modificada, encapsulando o herbicida atrazina (ATZ) em carreadores lipídicos nanoestruturados (CLNs) sem e contendo nanopartículas inorgânicas (magnéticas (Fe3O4@AO) e plasmônicas (Au@CTAB)), a fim de construir um sistema de liberação marcado que possa ser rastreado, auxiliando assim em futuras análises destes nanocarreadores no ambiente. Para o desenvolvimento das nanoformulações a técnica de emulsificação/evaporação solvente foi aplicada e diversos métodos físico-químicos foram empregados para a sua caracterização. As nanoformulações permaneceram estáveis por mais de 60 dias à temperatura ambiente. Além disso, os CLNs demostraram ter índice de polidispersão (PDI) < 0,2, potencial zeta entre -5,38 ± 0,27 a -23,5 ± 1,25 mV e uma eficiência de encapsulação maior que 90 % para a ATZ. As análises de microscopia eletrônica de varredura (MEV) revelaram ausência de agregados e morfologia esférica ao sistema. Além disso, as técnicas de espectroscopia de Infra... (Resumo completo, clicar acesso eletrônico abaixo)<br>Abstract: Numerous nanostructured systems have been developed for the transportation and modified release of crop protection products in recent years. Such systems have been shown to be a potential tool to reduce the toxicity of these active ingredients in the environment, as well as improving the efficiency of pesticides in the field. However, little is known about the fate, toxicity and mechanisms of action of these nanocarriers in the environment. In this sense, the objective of the present work was to develop potential modified release systems, encapsulating the herbicide atrazine (ATZ) in nanostructured lipid carriers (CLNs) without and containing inorganic (magnetic (Fe3O4 @ AO) and plasma (Au @ CTAB)) nanoparticles) , in order to build a marked release system that can be tracked, thus assisting in future analyzes of these nanocarriers in the environment. For the development of nanoformulations, the solvent emulsification / evaporation technique was applied and several physical-chemical methods were used for its characterization. The nanoformulations remained stable for more than 60 days at room temperature. In addition, CLNs have been shown to have a polydispersity index (PDI) <0.2, zeta potential between -5.38 ± 0.27 to -23.5 ± 1.25 mV and an encapsulation efficiency greater than 90% for the ATZ. Scanning electron microscopy (SEM) analyzes revealed the absence of aggregates and spherical morphology to the system. In addition, Infrared spectroscopy (FTIR) and X-ray (DRX) techniq... (Complete abstract click electronic access below)<br>Mestre
APA, Harvard, Vancouver, ISO, and other styles
9

Gaspari, Alexandre Rodrigues. "Avaliação biológica de nanocarreadores de doxorrubicina em células de câncer de bexiga." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/17/17137/tde-08012019-142441/.

Full text
Abstract:
O carcinoma da bexiga urinária (CB) é a segunda doença maligna mais frequente do trato urinário. Devido a baixa eficácia dos tratamentos intravesicais atuais (imunoterapia com BCG e quimioterapia), seja pelo baixo tempo de residência do fármaco na bexiga ou pela baixa permeabilidade no urotélio, novas estratégias que aumentem esse tempo de residência do fármaco e sua penetração na bexiga têm sido investigadas. Dentre estas estratégias pode-se citar os sistemas de liberação sustentada nanoestruturados, que liberam o fármaco gradativamente, protegem o fármaco encapsulado, aumenta a biodisponibilidade, aumentando a eficácia da terapia e diminuindo os efeitos adversos. Nesta linha, o objetivo desse trabalho foi produzir e utilizar carreadores lipídicos nanoestruturados (CLN) como sistema de carreamento de doxorrubicina (DOXO) e a sua avaliação biológica em células de câncer de bexiga. Os CLN, compostos por manteiga de Illipê (lipídeo sólido), ácido oleico (óleo) e o estabilizante Pluronic F68, foram preparados pelo método de emulsão a quente e sonicação. A caracterização físico-química do CLN foi realizada determinando o diâmetro hidrodinâmico médio e potencial zeta (carga superficial) por espalhamento de luz dinâmico (DLS), cristalinidade por calorimetria exploratória diferencial (DSC), eficiência de encapsulamento por espectrofotometria UV-vis, ensaio de citotoxicidade em células RT4 e análise de permeação ex vivo e in vivo das formulações aplicadas em bexiga de porco por microscopia confocal. O diâmetro hidrodinâmico médio dos CLN sem o fármaco foi de 103 nm e seu PdI (índice de polidispersão) igual a 0,2. O encapsulamento da DOXO aumentou o diâmetro dos CLN para 112 nm e o valor de PdI foi de 0,2. O baixo valor de PdI indica formulações com baixa polidispersão. Os valores de potencial zeta dos CLN sem e com DOXO foram ambos negativos, variando de -5 mV a -25 mV. Nos termogramas das amostras de CLN-DOXO não foi observado o pico referente a fusão da DOXO em 197,93ºC, indicando que o fármaco provavelmente está molecularmente disperso na matriz lipídica. Nos ensaios de citotoxicidade, a formulação CLN-DOXO mostrou-se mais citotóxica do que a DOXO livre em baixas concentrações (31-250 ng/mL). O valor de IC50 reduziu 2,1 vezes quando a DOXO foi encapsulada. Essa maior atividade antitumoral in vitro pode estar relacionada ao aumento do uptake celular como confirmado pelos ensaios de citometria de fluxo. No estudo de permeação ex vivo em bexiga de porco foram observadas permeações muito semelhantes das formulações de DOXO livre e encapsulada em CLN. Porém no ensaio in vivo a DOXO encapsulada permeou mais que a DOXO livre. Os resultados obtidos apontam para um promissor sistema de liberação de doxorrubicina para a terapia do câncer de bexiga.<br>Urinary bladder carcinoma (BC) is the second most common malignant disease of the urinary tract. Due to the low efficacy of current intravesical treatments (BCG immunotherapy and chemotherapy), either because of the low residence time of the drug in the bladder or due to low permeability in the urothelium, new strategies that increase the residence time of the drug and its penetration into the bladder have been investigated. These strategies include nanostructured sustained release systems, which release the drug gradually, protect the encapsulated drug, increase the bioavailability; increasing the effectiveness of the therapy and reducing side effects. In this line, the aim of this work was to produce and apply nanostructured lipid carriers (NLC) as a doxorubicin delivery system (DOXO) and its biological evaluation in bladder cancer cells. The NLC, composed by Illipe butter (solid lipid), oleic acid (oil) and Pluronic F68 stabilizer, were prepared by the hot emulsion and sonication method. The physical-chemical characterization of these NLC was performed by measured the mean hydrodynamic diameter and zeta potential (surface charge) by dynamic light scattering (DLS), crystallinity by differential scanning calorimetry (DSC), encapsulation efficiency by UV-vis spectrophotometry, cytotoxicity assay in RT4 cells and ex vivo and in vivo permeation assay of formulations applied to pig bladder by confocal microscopy. The mean hydrodynamic diameter of NLC without the drug was 103 nm and its PdI (polydispersity index) was 0.2. The encapsulation of DOXO increased the NLC diameter to 112 nm and the PdI value was 0.2. The low value of PdI indicates formulations with low polydispersion. The zeta potential values of the NLC without and with DOXO were both negative (-5 mV to -25 mV). In the thermograms of the NLC-DOXO sample the fusion peak of DOXO at 197.93 was not observed, indicating that the drug is molecularly dispersed in the lipid matrix. In the cytotoxicity assays, the NLC-DOXO formulation was more cytotoxic than free DOXO at low concentrations (31-250 ng/mL). The IC50 value was reduced 2.1 fold when DOXO was encapsulated. This increased in vitro antitumor activity may be related to increased cell uptake as confirmed by flow cytometry analysis. In the ex vivo permeation study in the pig bladder, a very similar permeation was observed between free and encapsulated DOXO. However, in the in vivo assay the encapsulated DOXO permeated more than free DOXO. The results indicates a promising release system of doxorubicin to bladder cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Barbosa, Raquel de Melo 1975. "Preparo e caracterização de nanopartículas lipídicas como carreadores do anestésico local dibucaína." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/314168.

Full text
Abstract:
Orientadores: Eneida de Paula, Daniele Ribeiro de Araújo<br>Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia<br>Made available in DSpace on 2018-08-24T00:52:12Z (GMT). No. of bitstreams: 1 Barbosa_RaqueldeMelo_D.pdf: 5424104 bytes, checksum: a7f0888c7fb32138387068083d5bf74f (MD5) Previous issue date: 2013<br>Resumo: Nanopartículas lipídicas sólidas (SLN) e carreadores lipídicos nanoestruturados (NLC) têm sido utilizados com sucesso como sistemas de liberação modificada. O anestésico local dibucaína (DBC) foi encapsulado em SLN e NLC objetivando aplicação tópica, para melhora de sua disponibilidade redução de efeitos adversos. As nanopartículas lipídicas foram preparadas pelas técnicas de sonicação (Son) ou homogeinização à alta pressão (HP), sendo utilizados palmitato de cetila (CP) ou miristato de miristila (MM) como matrizes lipídicas sólidas, acrescidos (NLC) ou não (SLN) de uma mistura de triglicerídeos de ácido cáprico e caprílico; poloxamer 188 foi usado como tensoativo. A DBC encapsulada foi quantificada por metodologia validada por cromatografia líquida de alta eficiência. As análises físico-químicas compreenderam diâmetro médio, potencial zeta, distribuição de tamanhos e morfologia das nanopartículas, percentual de encapsulação além de medidas de calorimetria exploratória de varredura (DSC), espectroscopia de infravermelho (FTIR), ressonância paramagnética eletrônica (RPE) e difração de raios X à baixo ângulo (SAXS). Medidas in vitro do perfil de liberação do fármaco, da estimativa de fluxo, deformação e elasticidade das partículas através de membranas artificiais e de toxicidade em cultura de células (fibloblastos 3T3 e queratinócitos HaCat) foram feitas. A estabilidade das amostras foi avaliada em função do tempo e testes de antinocicepção (tail flick, em ratos Wistar) foram usados para avaliar a atividade terapêutica in vivo. O diâmetro médio das partículas de SLN e NLC produzidas foi similar (ca. 200nm). A estabilidade física das nanopartículas foi satisfatória por até 240 dias de armazenamento a 4 ºC, principalmente para NLCMM/HP com e sem DBC, sugerindo que a metodologia de HP produz partículas mais estáveis. Todas as formulações apresentaram eficiência de encapsulação maior que 70%, sendo que NLCMMDBC/HP apresentou a maior encapsulação (90,54 ± 0,95%). Medidas de FTIR e DSC revelaram a DBC molecularmente dispersa na matriz lipídica das nanopartículas. Quanto à organização molecular das SLN e NLC, resultados de SAXS indicaram a existência de arranjos lipídicos lamelares no interior das SLN, não alterados pela adição da DBC; as medidas de RPE com marcadores de spin doxil-estearato revelaram espectros compatíveis com bicamadas, com maior organização molecular dos lipídios das SLN e NLC, após inserção da DBC. Ensaios in vitro confirmaram a liberação modificada da dibucaína associada às partículas, governada por difusão de Fick. Tanto a elasticidade quanto o fluxo das partículas in vitro apresentaram baixos valores evidenciando deposição das mesmas nas membranas com poros de 30 nm. A citotoxicidade intrínsica da DBC sobre ambos os tipos celulares foi reduzida após encapsulação nas SLN e NLC. O efeito analgésico in vivo da DBC a 0,05% aplicada topicamente (dispersa em gel de carbopol) aumentou significativamente após encapsulação nas formulações, em particular para SLNCPDBC liofilizada com o crioprotetor maltose. Assim, formulações de dibucaína em SLN ou NLC, preparadas com MM ou CP mostraram-se promissoras como bases para produtos farmacêuticos de liberação modificada, para anestesia dérmica<br>Abstract: Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), intended for topical application, were successfully prepared as sustained release systems for the encapsulation of the local anesthetic dibucaine (DBC), aiming to reduce its toxic effects and to improve its availability. The particles were prepared by two differents procedures: sonication (Son) or high pressure homogenization (HP), employing either cetyl palmitate (CP) or myristyl myristate (MM) as the solid lipid matrix, in the presence (NLC) or absence (SLN) of a mixture of capric and caprylic acids; poloxamer 188 was used as surfactant. DBC was quantified through a validated HPLC procedure. Physico-chemical analysis of the nanoparticles included measurements of size distribution, zeta potential, morphology, DBC encapsulation efficiency, as well as exploratory scanning calorimetry (DSC), infrared spectroscopy (FTIR), electron paramagnetic resonance (EPR) and small angle X-ray scattering (SAXS) tests. In vitro analysis of the release profile, flow and elasticity of the particles were performed through artificial membranes while toxicity was tested in 3T3 fibroblasts and HaCaT keratinocytes in culture. Stability of the formulations as a function of time was also measured. The therapeutic activity of the formulations was determined using antinociception tests (tail flick) in Wistar rats. SLN and NLC produced by both methodologies were similar (~200 nm), but HP produced more stable nanoparticles. The physical stability of the nanoparticles was satisfactory during a storage period of 240 days, especially for NLCMM/HP with or without DBC. All formulations showed encapsulation efficiencies higher than 70%, the greatest being assigned for NLCMMDBC/HP (90.54 ± 0.95%). FTIR and DSC revealed that DBC was molecularly dispersed in the lipid matrix of the nanoparticles. As for the SLN and NLC molecular packing, SAXS diffractrograms indicated the existence of lamellar repeats in SLN core region, which were not disturbed by the addition of DBC while EPR data with doxyl stearate probes revealed spectra compatible with bilayers, with higher molecular order in the presence of DBC. In vitro assays confirmed the prolonged release of dibucaine from the nanoparticles, by Fickian diffusion. Nanoparticles's elasticity and flow were low showing deposition on the surface of 30 nm pore membranes. The intrinsic cytotoxicity of DBC against both cell types was decreased, when encapsulated in SLN and NLC. The in vivo analgesic effect of 0.05% DBC topically applied (dispersed in carbopol gel) was significantly prolonged in the nanoparticle formulations, largely for SLNCPDBC lyophilized with maltosis as crioprotector. In conclusion, dibucaine formulations in SLN or NLC prepared with MM or CP are promising for the development of pharmaceutical products intended for prolonged dermal anesthesia<br>Doutorado<br>Bioquimica<br>Doutora em Biologia Funcional e Molecular
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Nanostructured lipid carriers"

1

Baisaeng, Nuttakorn. Ultra small nanostructured lipid carriers (usNLC) loaded with coenzyme Q 10. s.n.], 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nanostructured lipid carriers"

1

Wen, Jingyuan, Guanyu Chen, and Shuo Chen. "Nanostructured Lipid Carriers." In Emulsion-based Systems for Delivery of Food Active Compounds. John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119247159.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Müller, Rainer H., Ulrike Alexiev, Pricillia Sinambela, and Cornelia M. Keck. "Nanostructured Lipid Carriers (NLC): The Second Generation of Solid Lipid Nanoparticles." In Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-47862-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Üner, Melike. "Characterization and Imaging of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers." In Handbook of Nanoparticles. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-15338-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Üner, Melike. "Characterization and Imaging of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers." In Handbook of Nanoparticles. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13188-7_3-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Berti, Ignacio Rivero, Tanya Singh, Tugce Boztepe, Ignacio E. Leon, Ashok KUMAR Nadda, and Guillermo R. Castro. "CHAPTER 17. Design of Nanostructured Lipid Carriers and Hybrid Lipid Nanoparticles." In Nanoscience & Nanotechnology Series. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781788019613-00381.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

D’Souza, Anisha A., and Ranjita Shegokar. "Potential of oils in development of nanostructured lipid carriers." In Essential Oils and Nanotechnology for Treatment of Microbial Diseases. CRC Press, 2017. http://dx.doi.org/10.1201/9781315209241-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shah, Nirmal, Dipti Gohil, and Snehal Patel. "Nanostructured Lipid Carriers (NLCs): A Modern Versatile Drug Delivery Vehicle." In Nanocarriers: Drug Delivery System. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chakraborty, Tapash, Malay K. Das, Lopamudra Dutta, Biswajit Mukherjee, Sanjoy Das, and Anupam Sarma. "Successful Delivery of Zidovudine-Loaded Docosanol Nanostructured Lipid Carriers (Docosanol NLCs) into Rat Brain." In Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-06115-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Joshi, Medha D., Rashmi H. Prabhu, and Vandana B. Patravale. "Fabrication of Nanostructured Lipid Carriers (NLC)-Based Gels from Microemulsion Template for Delivery Through Skin." In Pharmaceutical Nanotechnology. Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9516-5_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chakraborty, Tapash, Malay K. Das, Lopamudra Dutta, Biswajit Mukherjee, Sanjoy Das, and Anupam Sarma. "Correction to: Successful Delivery of Zidovudine-Loaded Docosanol Nanostructured Lipid Carriers (Docosanol NLCs) into Rat Brain." In Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-06115-9_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nanostructured lipid carriers"

1

L. Kiss, Eszter, Erzsébet Csányi, and Mária Budai-Szűcs. "Nanostructured lipid carriers for ophthalmic use." In II. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2020. http://dx.doi.org/10.14232/syrptbrs.2020.op16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

L. Kiss, Eszter, Mária Budai-Szűcs, and Erzsébet Csányi. "Mucoadhesive nanostructured lipid carriers for ophthalmic use." In III. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2021. http://dx.doi.org/10.14232/syrptbrs.2021.op15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Paula, Eneida de. "LIPID-BASED (LIPOSOMES, NANOSTRUCTURED LIPID CARRIERS) DELIVERY SYSTEMS FOR LOCAL ANESTHETICS." In Encontro Anual da Biofísica 2018. Editora Blucher, 2018. http://dx.doi.org/10.5151/biofisica2018-42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eduardo Duran Caballero, Nelson, and Caroline Aparecida Dalben Rampazo. "Nanostructured Lipid Carriers containing natural lipids for cosmetic application on the skin." In XXIII Congresso de Iniciação Científica da Unicamp. Galoá, 2015. http://dx.doi.org/10.19146/pibic-2015-37126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, W., X. L. Yang, Y. L. Zhu, H. B. Chen, and H. B. Xu. "Nanostructured Lipid Carriers as Vehicles for Transdermal Iontophoretic Drug Delivery." In 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference. IEEE, 2005. http://dx.doi.org/10.1109/iembs.2005.1616648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ma, Q. H., Y. W. Wang, X. F. Lin, D. Luo, and N. Gu. "Preparation, Characterization and Photoprotection of Tocopherol Loaded Nanostructured Lipid Carriers." In 2007 IEEE/ICME International Conference on Complex Medical Engineering. IEEE, 2007. http://dx.doi.org/10.1109/iccme.2007.4381722.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tucak, Amina, Merima Sirbubalo, Andreas Zimmer, and Edina Vranić. "Cationic nanostructured lipid carriers (cNLCs) as drug delivery systems for miRNA." In II. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2020. http://dx.doi.org/10.14232/syrptbrs.2020.op24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Zhi-ping, Jun-biao Wu, Tong-sheng Chen, Qun Zhou, and Yi-fei Wang. "In vitroandin vivoantitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor." In SPIE BiOS, edited by Wei R. Chen. SPIE, 2015. http://dx.doi.org/10.1117/12.2079107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Torres, Joana, José Miguel Pereira, Renata Silva, et al. "Potential of Antioxidant-Loaded Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for the Management of Neurodegenerative Diseases." In ECMC 2022. MDPI, 2022. http://dx.doi.org/10.3390/ecmc2022-13417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Meng, Xiang-Ping, Fan Shi, Hai-Jie Li, et al. "Evaluation of free radical scavenging and anti-oxidative capacity of polydatin-nanostructured lipid carriers." In SPIE/COS Photonics Asia, edited by Qingming Luo, Xingde Li, Ying Gu, and Yuguo Tang. SPIE, 2016. http://dx.doi.org/10.1117/12.2245532.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography